piracetam has been researched along with Idiopathic Parkinson Disease in 9 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Levodopa-treated PD participants with LID (n = 38) received LEV 500 mg/day, were assessed, titrated to 1,000 mg/day and reassessed, before and after crossover." | 2.76 | Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease. ( Konitsiotis, S; Peterson, D; Stathis, P; Tagaris, G, 2011) |
| "Levetiracetam was well tolerated at doses up to 2000 mg per day, but we did not detect any antidyskinetic properties." | 2.76 | A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease. ( Alty, JE; Goy, AG; Kempster, PA; Raghav, S; Reutens, DC; Wong, KK, 2011) |
| "We studied 6 patients with myoclonus elicited by flash stimulation (1-15 Hz)." | 1.29 | The pathophysiology and pharmacology of photic cortical reflex myoclonus. ( Artieda, J; Obeso, JA, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (33.33) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Singh, S | 1 |
| Schwankhaus, J | 1 |
| Stathis, P | 1 |
| Konitsiotis, S | 1 |
| Tagaris, G | 1 |
| Peterson, D | 1 |
| Wong, KK | 1 |
| Alty, JE | 1 |
| Goy, AG | 1 |
| Raghav, S | 1 |
| Reutens, DC | 1 |
| Kempster, PA | 1 |
| Tousi, B | 1 |
| Subramanian, T | 1 |
| Zesiewicz, TA | 1 |
| Sullivan, KL | 1 |
| Maldonado, JL | 1 |
| Tatum, WO | 1 |
| Hauser, RA | 1 |
| Kurako, IuL | 1 |
| Volianskiĭ, VE | 1 |
| Finke, J | 1 |
| Artieda, J | 1 |
| Obeso, JA | 1 |
| Oepen, G | 1 |
| Eisele, K | 1 |
| Thoden, U | 1 |
| Birg, W | 1 |
1 review available for piracetam and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
[New directions in contemporary pharmacotherapy of parkinsonism (review)].
Topics: Adrenergic beta-Antagonists; Anti-Anxiety Agents; Antiparkinson Agents; Apomorphine; Aromatic Amino | 1984 |
2 trials available for piracetam and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyski | 2011 |
A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease.
Topics: Anticonvulsants; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Ind | 2011 |
6 other studies available for piracetam and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Olfactory disturbance in Parkinson disease.
Topics: Aged; Anticonvulsants; Antiparkinson Agents; Antipsychotic Agents; Aripiprazole; Biomarkers; Brain; | 2009 |
The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson's disease.
Topics: Aged; Anticonvulsants; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levetiracetam | 2005 |
Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease.
Topics: Aged; Anticonvulsants; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levetiracetam | 2005 |
[Antiparkinson medication: increasing effectiveness with piracetam].
Topics: Aged; Antiparkinson Agents; Drug Synergism; Female; Humans; Male; Middle Aged; Parkinson Disease; Pi | 1980 |
The pathophysiology and pharmacology of photic cortical reflex myoclonus.
Topics: 5-Hydroxytryptophan; Aged; Aged, 80 and over; Ataxia; Cerebral Cortex; Dopamine Agents; Electroencep | 1993 |
Piracetam improves visuomotor and cognitive deficits in early Parkinsonism--a pilot study.
Topics: Aged; Cognition Disorders; Female; Humans; Male; Middle Aged; Parkinson Disease; Piracetam; Psychomo | 1985 |